Price Alert

Stevanato Group S.p.A. (STVN)

NYSE: STVN · Real-Time Price · USD

22.19

-0.17 (-0.76%)

At close: Aug 14, 2025, 3:59 PM

22.17

-0.09%

After-hours: Aug 14, 2025, 05:17 PM EDT

-0.76% (1D)

Bid	21.52
Market Cap	6.06B
Revenue (ttm)	1.15B
Net Income (ttm)	134.56M
EPS (ttm)	0.57
PE Ratio (ttm)	38.93
Forward PE	31.35
Analyst	Hold

Ask	24.06
Volume	246,897
Avg. Volume (20D)	331,925
Open	22.48
Previous Close	22.36
Day's Range	22.19 - 22.78
52-Week Range	17.12 - 28.00
Beta	0.55

About STVN

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol STVN

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for STVN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Stevanato S.p.A. has released their quartely earnings on Aug 5, 2025:

Revenue of $317.46M exceeds estimates by $14.63M, with 13.59% YoY growth.

EPS of 0.13 exceeds estimates by 0.02, with 30.00% YoY growth.

Next Earnings Release

Stevanato Group S.p.A. is scheduled to release its earnings on Nov 4, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

-9.73%

Stevanato Group shares are trading lower following... Unlock content with Pro Subscription

3 months ago

+3.12%

Stevanato Group shares are trading higher after the company reported a year-over-year increase in Q1 sales results.

News

2 days ago · zacks.com

USNA vs. STVN: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Drugs sector might want to consider either USANA Health Sciences (USNA) or Stevanato Group (STVN). But which of these two stocks presents investors with t...

1 week ago · zacks.com

Stevanato Group (STVN) Q2 Earnings and Revenues Beat Estimates

Stevanato Group (STVN) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.1 per share a year ago.

1 week ago · businesswire.com

Stevanato Group Reports Revenue of €280.0 Million for the Second Quarter of 2025

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...

2 weeks ago · zacks.com

Stevanato Group (STVN) Earnings Expected to Grow: Should You Buy?

Stevanato (STVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago · zacks.com

MKKGY or STVN: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Drugs stocks are likely familiar with Merck KGaA (MKKGY) and Stevanato Group (STVN). But which of these two stocks offers value investors a better bang for their buck...

2 weeks ago · zacks.com

Stevanato (STVN) Soars 10.0%: Is Further Upside Left in the Stock?

Stevanato (STVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the r...

3 weeks ago · businesswire.com

Stevanato Group Secures €200 Million in Financing from BNL BNP Paribas, Cassa Depositi e Prestiti, and Banco BPM to Fund Ongoing CAPEX Investments in Italy and the U.S.

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and lif...

3 weeks ago · businesswire.com

Stevanato Group to Report Second Quarter 2025 Financial Results on August 5, 2025

3 weeks ago · seekingalpha.com

Stevanato: Expansion In Italy And The U.S. Will Pave The Way

The new facility in the U.S. expects to generate €500 million in annual revenues by 2028. The global drug containment solution market is expected to grow at an 8% CAGR from 2024 to 2030. In this marke...

1 month ago · zacks.com

CPRX or STVN: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Drugs stocks are likely familiar with Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks offers value investors a better bang fo...

Load More News